DexCom (DXCM) Upgraded at BidaskClub

BidaskClub upgraded shares of DexCom (NASDAQ:DXCM) from a buy rating to a strong-buy rating in a research note issued to investors on Thursday.

Several other research firms have also commented on DXCM. Barclays assumed coverage on DexCom in a research report on Friday, September 15th. They issued an equal weight rating and a $76.00 price objective on the stock. Robert W. Baird reissued a hold rating and issued a $79.00 price objective on shares of DexCom in a research report on Sunday, September 10th. BMO Capital Markets reissued a buy rating and issued a $90.00 price objective on shares of DexCom in a research report on Friday, September 8th. Piper Jaffray Companies reissued an overweight rating and issued a $87.00 price objective on shares of DexCom in a research report on Friday, September 8th. Finally, Northland Securities assumed coverage on DexCom in a research report on Tuesday, September 26th. They issued an outperform rating and a $85.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. DexCom has a consensus rating of Buy and a consensus target price of $72.31.

DexCom (NASDAQ:DXCM) traded up $1.01 during trading hours on Thursday, reaching $53.26. The company’s stock had a trading volume of 2,968,100 shares, compared to its average volume of 2,884,975. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. DexCom has a one year low of $42.62 and a one year high of $88.80. The stock has a market capitalization of $4,550.00, a price-to-earnings ratio of -93.44 and a beta of 0.31.

In other DexCom news, Director Steven R. Altman bought 10,000 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were acquired at an average cost of $49.61 per share, with a total value of $496,100.00. Following the completion of the transaction, the director now owns 4,353 shares in the company, valued at $215,952.33. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Richard Doubleday sold 1,635 shares of DexCom stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $44.82, for a total value of $73,280.70. Following the sale, the executive vice president now directly owns 65,049 shares in the company, valued at $2,915,496.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,140 shares of company stock worth $2,158,576. Corporate insiders own 1.70% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Rathbone Brothers plc increased its holdings in DexCom by 5.3% in the second quarter. Rathbone Brothers plc now owns 4,000 shares of the medical device company’s stock valued at $293,000 after buying an additional 200 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in DexCom by 12.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock valued at $238,000 after buying an additional 354 shares during the last quarter. Utah Retirement Systems increased its holdings in DexCom by 4.0% in the second quarter. Utah Retirement Systems now owns 15,600 shares of the medical device company’s stock valued at $1,141,000 after buying an additional 600 shares during the last quarter. Ithaka Group LLC increased its holdings in DexCom by 0.9% in the second quarter. Ithaka Group LLC now owns 81,416 shares of the medical device company’s stock valued at $5,956,000 after buying an additional 703 shares during the last quarter. Finally, Advisor Group Inc. increased its holdings in DexCom by 104.9% in the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after buying an additional 837 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.com-unik.info/2018/01/08/dexcom-dxcm-upgraded-at-bidaskclub.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

What are top analysts saying about DexCom? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DexCom and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit